After Clearing CRL, ARS Wins FDA Approval of First Nasal Spray for Anaphylaxis

After a bumpy road to approval, the FDA has approved ARS Pharmaceuticals’ neffy (epinephrine nasal spray) for the emergency treatment of Type I allergic reactions, including those that are life-threatening (anaphylaxis), in adult and pediatric patients who weigh at least 66 pounds.
Source: Drug Industry Daily